The World’s First Ovarian Tissue Dual-Activation Technology Selected into the 2025 "Shandong Outstanding Achievements Report" Project
Release time:
2025-10-13
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Addressing Infertility Challenges and Nurturing Hope for Childbearing
Shandong Silver Med Life Science Research Institute (hereinafter referred to as "Silver Med Institute") collaborated with a team led by Professor Wang Huiying and Dr. Jin Bo from Beijing University of Chinese Medicine Shenzhen Hospital to develop this "ovarian dual-activation" technology, marking another milestone in cryobiomedical science. By employing a "cryopreservation + PFC" dual-activation approach for ovarian tissue, the technology has enabled patients to achieve natural conception. To date, the first healthy baby born through this method has been delivered safely.
It is reported that this is the world’s first case of successful natural conception and live birth achieved by activating ovaries using this method. The application of this technology not only brings hope to patients with premature ovarian failure (POF) and infertility but also provides a brand-new solution for fertility preservation in female cancer patients of childbearing age.
World’s First Ovarian Dual-Activation Technology
The team innovatively combined the in vitro activation of primordial follicles (IVA) with autologous venous-derived cytokine (PFC) technology, offering safer, more effective, and personalized treatment options for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
PFC technology involves concentrating, activating, and isolating various cell growth factors, cytokines, and related proteins from autologous venous blood using specialized methods, followed by standardized preparation processes such as lyophilization. Clinical studies have confirmed that these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles in the ovaries, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, traditional methods struggle to activate and grow ovarian follicles. The team’s innovative IVA technology involves extracting a small sample of ovarian cortical tissue via laparoscopic surgery, combining it with cryopreservation and revival techniques, subjecting it to ex vivo cryogenic activation in the lab, and performing in situ transplantation approximately one hour later. This process softens and expands the atrophied ovarian tissue. Post-operative evaluations show improvements in ovarian volume, follicle count, and ovarian artery blood flow, with hormone levels returning to normal.
Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual-activation technology not only provides a safe and reliable new option for POI/POR patients but also offers choices for fertility preservation in cancer patients.
Current fertility preservation methods primarily include oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation. For males, sperm cryopreservation is the main approach. Among these, ovarian tissue cryopreservation and transplantation are internationally recognized as the most promising methods for fertility protection, serving as the sole option for prepubertal girls and childbearing-age women undergoing non-deferrable anticancer treatment.
Additionally, experts highlight the technology’s potential application in menopausal regulation. By cryopreserving ovarian tissue at a young age and transplanting it later in life, it may delay menopause, reduce reliance on hormone therapy, and slow aging.
Looking ahead, the Silver Med Institute will collaborate with Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) to deepen research on original technologies in "fertility preservation," aiming to establish a comprehensive fertility preservation system. By applying cryopreservation technology more broadly and effectively in clinical practice, they strive to contribute to building a fertility-friendly society.
Latest developments
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
The significance of life extension lies not only in technological breakthroughs but also in the shared belief of every individual who believes in "a better future." With faith as their torch, these fellow travelers join hands, pooling their strength to stride forward together. We firmly believe that as this steadfast support converges into a powerful force, it will propel the Yinfeng Life Extension Plan to gain broader attention, inject continuous momentum into the development of cryobiomedicine, and illuminate the next chapter of human civilization.
Over the two days, the symposium was not only a collision of ideas but also seeds sown to advance social progress in life culture. The Shandong Yinfeng Life Science Public Welfare Foundation will continue to use technology as wings and culture as roots, collaborating with all sectors of society to enhance the quality of life for the Chinese people and build a human-centered life care system.
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
